| Thompson Peter A. |
Non-Executive Director |
Edgewise Therapeutics, Inc. (EWTX)
|
2024-01-23 |
$11.00 |
58.8% |
454,545
|
$4,999,995 |
| Thompson Peter A. |
Non-Executive Director |
ARS Pharmaceuticals, Inc. (SPRY)
|
2023-08-29 |
$6.20 |
89.5% |
500,000
|
$3,100,000 |
| Thompson Peter A. |
Non-Executive Director |
Edgewise Therapeutics, Inc. (EWTX)
|
2022-09-16 |
$10.32 |
69.3% |
484,496
|
$4,999,999 |
| Thompson Peter A. |
Non-Executive Director |
Edgewise Therapeutics, Inc. (EWTX)
|
2022-05-18 |
$7.21 |
142.3% |
138,000
|
$994,980 |
| Thompson Peter A. |
Non-Executive Director |
ALPINE IMMUNE SCIENCES, INC. (ALPN)
|
2021-09-17 |
$9.40 |
591.2% |
1,010,637
|
$9,499,988 |
| Thompson Peter A. |
Non-Executive Director |
Janux Therapeutics, Inc. (JANX)
|
2021-06-15 |
$17.00 |
157.1% |
705,853
|
$11,999,501 |
| Thompson Peter A. |
Non-Executive Director |
Edgewise Therapeutics, Inc. (EWTX)
|
2021-03-30 |
$16.00 |
9.2% |
359,375
|
$5,750,000 |
| Thompson Peter A. |
Non-Executive Director |
Corvus Pharmaceuticals, Inc. (CRVS)
|
2021-02-17 |
$3.50 |
14.3% |
1,285,714
|
$4,499,999 |
| Thompson Peter A. |
Non-Executive Director |
Decibel Therapeutics, Inc. (DBTX)
|
2021-02-17 |
$18.00 |
-72.7% |
1,666,666
|
$29,999,988 |
| Thompson Peter A. |
Non-Executive Director |
PMV Pharmaceuticals, Inc. (PMVP)
|
2020-09-25 |
$18.00 |
-91.5% |
950,000
|
$17,100,000 |
|
|
|
|
|
Return |
Profit / (loss) |
Cost |
|
|
|
Total |
|
53.1% |
$49,318,343 |
$92,944,450 |